BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
📌TL;DR
Gilead (GILD) announced a definitive agreement to acquire Munich-based Tubulis GmbH for up to $5B ($3.15B upfront + $1.85B in milestones), adding a next-generation antibody-drug conjugate (ADC) platform and two clinical-stage oncology candidates. This is Gilead's third acquisition since late February, totaling approximately $15B across three deals.
Neurocrine Biosciences (NBIX) agreed to acquire Soleno Therapeutics (SLNO) for $2.9B ($53/share, 34% premium). The deal adds Vykat XR, the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, which generated $190M in 2025 revenue. This is Neurocrine's largest acquisition in its 34-year history.
AbbVie listed Humira on TrumpRx at a steep discount as the Section 232 tariff threat solidifies. More companies are expected to follow.
Foundayo (orforglipron) continues its early rollout through LillyDirect. Retail pharmacy availability is expanding.
⚡ Executive Takeaway
Gilead is on a deal spree that is hard to overstate. In roughly six weeks, the company has committed approximately $15 billion across three acquisitions: Arcellx for $7.8B (CAR-T, late February), Ouro Medicines for $2.18B (autoimmune TCE, late March), and now Tubulis for up to $5B (ADCs, this week). That is the most aggressive acquisition run in Gilead's history and one of the most concentrated capital deployment periods any single pharma company has executed in recent memory. CEO Daniel O'Day called the Tubulis deal "a significant milestone in Gilead's progress in oncology." RBC Capital Markets called it "a strategically sound bolt-on." Meanwhile, Neurocrine made its largest acquisition ever, paying $2.9B for Soleno's Vykat XR in Prader-Willi syndrome. The deal adds $190M in 2025 revenue and a potential blockbuster in a rare disease space with no competition. The M&A pace that defined Q1 has carried directly into Q2 without slowing down. 👉 Read Full Analysis
🔮 What To Watch
Gilead's Q2 M&A Capacity: After $15B in deals, watch whether Gilead has appetite for a fourth acquisition or pivots to integration mode. The Tubulis deal will be financed with cash on hand and senior unsecured notes.
Foundayo Launch Trajectory: LillyDirect shipping continues. Retail pharmacy and telehealth provider rollout is expanding. Early prescription volume data will be the first competitive signal against Novo's oral Wegovy.
Section 232 Tariff Responses: AbbVie's Humira listing on TrumpRx signals that the tariff structure is working as designed: companies are making pricing concessions to secure tariff exemptions. More companies will follow.
Neurocrine/Soleno Integration: Vykat XR generated $92M in Q4 2025 alone, suggesting accelerating adoption. Neurocrine CEO Kyle Gano said the data shows "all the profile aspects of a potential blockbuster."
🚀 Top Story
Gilead's $5B Tubulis Acquisition Caps a $15B Deal Spree in 6 Weeks GILD
What Happened: Gilead Sciences announced a definitive agreement to acquire Tubulis GmbH, a private Munich-based biotech developing next-generation antibody-drug conjugates (ADCs), for $3.15B upfront in cash plus up to $1.85B in milestone payments ($5B total potential value). The deal builds on a research collaboration the two companies established in December 2024. Tubulis will operate as a dedicated ADC research organization within Gilead, with Munich serving as a hub for ADC innovation. Close expected Q2 2026.
The Assets: Tubulis's lead candidate, TUB-040, is a NaPi2b-directed topoisomerase-I inhibitor ADC currently in Phase 1b/2 development for platinum-resistant ovarian cancer and non-small cell lung cancer. At ESMO 2025, TUB-040 demonstrated a 59% overall response rate in platinum-resistant ovarian cancer, which RBC called "validating a potentially novel target." Gilead also acquires TUB-030, a 5T4-targeted ADC with promising early clinical data across various solid tumors, plus a proprietary next-generation ADC platform (Tubutecan linker-payload technology) designed to improve stability and selectivity of payload delivery.
Executive Impact: This is Gilead's third acquisition since late February. The running total: Arcellx for $7.8B (CAR-T for multiple myeloma), Ouro Medicines for $2.18B (autoimmune TCE), and now Tubulis for $5B (oncology ADCs). That is approximately $15B deployed across three deals in roughly six weeks. The strategy is clear: Gilead is systematically building franchises in cell therapy, autoimmune disease, and ADC oncology to diversify beyond its HIV and hepatitis base as Veklury revenues decline. Tubulis raised €344M ($401M) in a Series C last October. Tubulis also has a partnership with Bristol Myers Squibb.
🏢 Corporate & Business Developments
Neurocrine Pays $2.9B for Soleno and Its Prader-Willi Drug NBIX | SLNO
What Happened: Neurocrine Biosciences announced a definitive agreement to acquire Soleno Therapeutics for $53 per share in cash, a total equity value of $2.9B. The deal represents a 34% premium to Soleno's closing price on April 2 and a 51% premium to the 30-day VWAP. This is Neurocrine's largest acquisition in its 34-year history. Close expected within 90 days, funded with cash on hand and modest prepayable debt. SLNO shares surged 33% on the news.
The Asset: Soleno's Vykat XR (diazoxide choline) is the first and only FDA-approved treatment for hyperphagia in adults and children 4 years and older with Prader-Willi syndrome, a rare genetic disorder affecting approximately 10,000 people in the U.S. that causes compulsive food-seeking behavior. Vykat XR was approved March 2025 and generated $190.4M in 2025 revenue, including $92M in Q4 alone. The drug swung Soleno into profitability in 2025 with $20.8M in net income. IP extends into the mid-2040s.
Executive Impact: Neurocrine CEO Kyle Gano said Vykat XR has "all the profile aspects of a potential blockbuster in the making." The acquisition positions Neurocrine at the intersection of neuroscience and endocrinology, with the company now holding three first-in-class medicines: INGREZZA (valbenazine for tardive dyskinesia), CRENESSITY (crinecerfont for congenital adrenal hyperplasia), and Vykat XR. The deal comes months after Neurocrine unveiled a preclinical obesity pipeline, signaling a broader metabolic strategy. No direct competition exists for Vykat XR in hyperphagia, giving Neurocrine a runway to deepen market penetration.
AbbVie Lists Humira on TrumpRx at Steep Discount ABBV
AbbVie has listed Humira on TrumpRx, the administration's direct-to-consumer drug pricing platform, at a steep discount, according to BioSpace. The move comes as the Section 232 tariff structure solidifies and companies seek to secure tariff exemptions through MFN pricing agreements. More companies are expected to follow. This is exactly the behavior the administration's tariff framework was designed to incentivize.
📅 The Week Ahead
Now: Foundayo (orforglipron) retail pharmacy rollout expanding
April: Novo Nordisk Wegovy HD U.S. launch continues
April: Heart Rhythm 2026 conference
Q2 2026: Gilead/Tubulis close expected
Q2 2026: Gilead/Arcellx close expected
Within 90 days: Neurocrine/Soleno close expected
🔒 BioMed Nexus Pro — Institutional Intelligence Brief
In Today's Pro Brief:
🧠 Gilead's $15B Deal Spree: Why three acquisitions in six weeks reveals a company racing to rebuild its growth profile
💊 Neurocrine's Blockbuster Bet: Why Vykat XR's $190M first year and zero competition make the $2.9B price rational
📊 M&A Running Tally: Q2 has already added nearly $8B in new deal value in the first week
🎯 Updated catalyst calendar
Selective 2026 sponsorship placements are available
Reply directly to discuss a partnership or submit an inquiry here